Tempus AI partnered with Angiosarcoma Awareness to advance rare cancer research using the company’s computational resources and multiomic datasets. The collaboration incorporates roughly 600 deidentified angiosarcoma patient records with paired DNA and RNA sequencing plus clinical information. The study expands on the Angiosarcoma Project, initially created by the Broad Institute, Dana-Farber Cancer Institute and Count Me In to help patients securely share clinical data and biosamples. That infrastructure has since expanded to include other rare cancers, reflecting a wider push toward data pooling for indications that historically lacked scalable cohorts. Tempus and the nonprofit framed the project around precision medicine goals, including identifying biological signals that can support treatment selection and improve future clinical planning. The near-term impact is dataset augmentation for discovery, with longer-range value depending on how quickly insights translate into testable biomarkers and therapeutic hypotheses in rare disease.